Prognostic and clinicopathological value of the prognostic nutritional index in prostate cancer treated with androgen deprivation therapy: a systematic review and meta-analysis.
메타분석
1/5 보강
PICO 자동 추출 (휴리스틱, conf 2/4)
유사 논문P · Population 대상 환자/모집단
847 patients were included.
I · Intervention 중재 / 시술
추출되지 않음
C · Comparison 대조 / 비교
추출되지 않음
O · Outcome 결과 / 결론
[CONCLUSIONS] In the context of ADT-based systemic therapy, low PNI is a significant predictor of poor survival and aggressive disease features, supporting its potential as a readily available biomarker for risk stratification and prognostic assessment in prostate cancer patients. [SYSTEMATIC REVIEW REGISTRATION] https://www.crd.york.ac.uk/prospero/, identifier CRD420251145397.
[BACKGROUND] The prognostic nutritional index (PNI) has been associated with survival outcomes in multiple solid tumors, yet its prognostic relevance in prostate cancer patients undergoing androgen de
- p-value p = 0.003
- 95% CI 1.756-2.469
- OR 1.404
- HR 2.082
- 연구 설계 SYSTEMATIC REVIEW
APA
Huang H, Hu J, et al. (2026). Prognostic and clinicopathological value of the prognostic nutritional index in prostate cancer treated with androgen deprivation therapy: a systematic review and meta-analysis.. Frontiers in oncology, 16, 1794606. https://doi.org/10.3389/fonc.2026.1794606
MLA
Huang H, et al.. "Prognostic and clinicopathological value of the prognostic nutritional index in prostate cancer treated with androgen deprivation therapy: a systematic review and meta-analysis.." Frontiers in oncology, vol. 16, 2026, pp. 1794606.
PMID
41883977
Abstract
[BACKGROUND] The prognostic nutritional index (PNI) has been associated with survival outcomes in multiple solid tumors, yet its prognostic relevance in prostate cancer patients undergoing androgen deprivation therapy (ADT)-based systemic treatment remains insufficiently characterized.
[METHODS] We systematically searched PubMed, Embase, Cochrane Library, Web of Science, and China National Knowledge Infrastructure (CNKI) from database inception to September 11, 2025. Pooled hazard ratios (HRs) with 95% confidence intervals (CIs) were used to assess the association between PNI and survival outcomes; pooled odds ratios (ORs) with 95% CIs evaluated links with clinicopathological features. Subgroup analyses explored heterogeneity sources.
[RESULTS] Ten retrospective studies involving 1, 847 patients were included. Low PNI was significantly associated with worse overall survival (HR = 2.082, 95% CI: 1.756-2.469, < 0.001). Due to heterogeneous definitions of disease progression across studies, progression-related endpoints were analyzed separately by type. Low PNI consistently predicted inferior outcomes across multiple progression-free survival metrics: PFS (HR = 1.606, 95% CI: 1.328-1.942), radiographic PFS (rPFS; HR = 2.315, 95% CI: 1.525-3.514), and PSA-PFS (HR = 3.176, 95% CI: 2.169-4.652) (all < 0.001). Subgroup analyses supported result robustness. Additionally, low PNI correlated significantly with Gleason score >7 (OR = 1.404, = 0.018), bone metastasis (OR = 1.433, = 0.015), LATITUDE high-risk status (OR = 1.898, p = 0.003), and CHAARTED-defined high tumor burden (OR = 1.950, = 0.001), but not with age, visceral metastases, or EAU high-risk classification.
[CONCLUSIONS] In the context of ADT-based systemic therapy, low PNI is a significant predictor of poor survival and aggressive disease features, supporting its potential as a readily available biomarker for risk stratification and prognostic assessment in prostate cancer patients.
[SYSTEMATIC REVIEW REGISTRATION] https://www.crd.york.ac.uk/prospero/, identifier CRD420251145397.
[METHODS] We systematically searched PubMed, Embase, Cochrane Library, Web of Science, and China National Knowledge Infrastructure (CNKI) from database inception to September 11, 2025. Pooled hazard ratios (HRs) with 95% confidence intervals (CIs) were used to assess the association between PNI and survival outcomes; pooled odds ratios (ORs) with 95% CIs evaluated links with clinicopathological features. Subgroup analyses explored heterogeneity sources.
[RESULTS] Ten retrospective studies involving 1, 847 patients were included. Low PNI was significantly associated with worse overall survival (HR = 2.082, 95% CI: 1.756-2.469, < 0.001). Due to heterogeneous definitions of disease progression across studies, progression-related endpoints were analyzed separately by type. Low PNI consistently predicted inferior outcomes across multiple progression-free survival metrics: PFS (HR = 1.606, 95% CI: 1.328-1.942), radiographic PFS (rPFS; HR = 2.315, 95% CI: 1.525-3.514), and PSA-PFS (HR = 3.176, 95% CI: 2.169-4.652) (all < 0.001). Subgroup analyses supported result robustness. Additionally, low PNI correlated significantly with Gleason score >7 (OR = 1.404, = 0.018), bone metastasis (OR = 1.433, = 0.015), LATITUDE high-risk status (OR = 1.898, p = 0.003), and CHAARTED-defined high tumor burden (OR = 1.950, = 0.001), but not with age, visceral metastases, or EAU high-risk classification.
[CONCLUSIONS] In the context of ADT-based systemic therapy, low PNI is a significant predictor of poor survival and aggressive disease features, supporting its potential as a readily available biomarker for risk stratification and prognostic assessment in prostate cancer patients.
[SYSTEMATIC REVIEW REGISTRATION] https://www.crd.york.ac.uk/prospero/, identifier CRD420251145397.
같은 제1저자의 인용 많은 논문 (5)
- A Machine Learning Approach to Predicting Donor Site Complications Following DIEP Flap Harvest.
- Umbilical Complications following DIEP Flap Breast Reconstruction: Demonstrating the Added Benefit of Preoperative Imaging.
- TAZ WW Domain-Mediated Regulation of Gluconeogenesis and Tumorigenesis in Hepatocellular Carcinoma through Interaction with the Glucocorticoid Receptor.
- Targeting the CCL5/CCR5-PI3K-AKT axis suppresses hepatic stellate cell-induced breast cancer metastasis.
- Decoding prostate cancer therapy resistance and novel therapeutic strategies.